Company intelligence / Profile preview
SPARK Biopharma
Seoul, South Koreasparkbiopharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead asset SB-17170 is undergoing phase 1 clinical trials in oncology. Additional pipeline assets in oncology and fibrosis are in preclinical validation with an IND targeted for 2024 (as of 2023 information).
- Therapeutic areas
- OncologyImmunologyPulmonology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on SPARK Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPARK Biopharma.